MDL Track
MDL 2924
S.D. Fla.
Zantac (ranitidine) products liability
851 pending
Pharmaceutical · claims concerning NDMA contamination and alleged cancer risk from ranitidine products
Defendant
GlaxoSmithKline LLC
MDL / Track
MDL 2924
S.D. Fla.
Judge
Judge Robin L. Rosenberg
Plaintiffs
roughly 1,100 pending (851 per JPML's March 2, 2026 report, plus ~250 new filings tracked since)
Bellwether / Trial
Settlement Status
Track litigations for free. Save this matter, capture notes, and monitor live signals.
Case overview
The Delaware Superior Court dismissed approximately 80,000 pre-December 2025 Zantac cases on April 14, 2026, applying Daubert exclusion of plaintiffs' general causation experts retroactively to all filed claims, following the Delaware Supreme Court's July 10, 2025 reversal in In re Zantac (Ranitidine) Litig., No. 255, 2024, 2025 WL 1903760 (Del.), which held that general causation analysis must focus on ranitidine itself rather than its NDMA component. The federal MDL (No. 9:20-md-02924, S.D. Fla., Judge Robin L. Rosenberg) remains dismissed after Judge Rosenberg's December 6, 2022, 341-page Daubert order (644 F. Supp. 3d 1075) excluding all ten plaintiffs' experts, with appeal argued October 2025 and decision pending in the Eleventh Circuit. GSK previously settled approximately 80,000 state court claims for up to $2.2 billion in October 2024 per SEC Form 6-K; Connecticut bellwether trials against Boehringer Ingelheim are scheduled for March 2028.
Causation Theory
Plaintiffs' core theory alleges that ranitidine's molecular structure is inherently unstable and degrades into N-nitrosodimethylamine (NDMA) during normal storage and distribution, with heat and time accelerating accumulation above FDA safety thresholds. Valisure's September 13, 2019 citizen petition reported NDMA exceeding 3,000,000 ng per tablet across tested lots, prompting FDA testing and the April 1, 2020 market withdrawal request. However, the FDA-commissioned human clinical trial found no concerning increases in urinary NDMA after ranitidine administration with high-nitrite meals, and a 2022 nationwide Danish cohort study in Cancer Epidemiology, Biomarkers & Prevention analyzing 14-year follow-up data found no consistent evidence of increased upper gastrointestinal cancer risk among ranitidine users compared to other H2-blocker or proton pump inhibitor users.
Case Management Orders
Litigation status
The federal MDL 2924 remains procedurally dormant pending the Eleventh Circuit's decision on Judge Robin L. Rosenberg's Daubert dismissal, argued October 10, 2025; no ruling has issued as of September 2026. Delaware Superior Court Judge Francis J. Jones dismissed approximately 80,000 pre-December 2025 cases on April 13-14, 2026, applying the Delaware Supreme Court's July 10, 2025 mandate for stricter expert gatekeeping. Connecticut state court is now the sole active trial track, with bellwether trials against Boehringer Ingelheim scheduled to begin March 14, 2028.
MDL Track
MDL 2924
S.D. Fla.
Zantac (ranitidine) products liability
851 pending
State Court Activity
Connecticut: active bellwether track vs. Boehringer Ingelheim, trials begin March 14, 2028; Delaware: ~80,000 cases dismissed April 2026; California: JCCP 5150 continues with manufacturing defect theory litigation per September 2025 order
MDL 2924 Leadership
Plaintiff Leadership
Co-Lead Counsel
Defense Leadership
Co-Lead Counsel
Geographic exposure
GSK's October 2024 $2.2 billion settlement resolved approximately 80,000 state-court claims without admission of liability. Sanofi settled roughly 4,000 claims for approximately $100 million ($25,000 per claimant), excluding approximately 20,000 Delaware claims. Pfizer reached confidential settlements in Connecticut. Boehringer Ingelheim accumulated eight consecutive trial wins across colorectal, prostate, bladder, and kidney cancer claims without a plaintiff verdict. FDA's April 2020 recall serves as the primary discovery rule trigger date; SOL windows have closed or are closing rapidly in states with shorter statutes.
Delaware Superior Court dismissed approximately 80,000 pre-December 2025 Zantac cases on April 14, 2026, in In re Zantac (Ranitidine) Litigation, No. 255, 2024, after the Delaware Supreme Court reversed plaintiffs' expert admissibility on July 10, 2025. Judge Francis J. Jones held plaintiffs were 'not entitled to a mulligan' under Delaware's causation standard. The dismissal included roughly 40,000 cases naming Boehringer Ingelheim specifically.
JCCP 5150 continues as an active coordinated proceeding with approximately 4,000 consolidated cases. September 2025 ruling allowed plaintiffs to pursue a manufacturing defect theory. Alameda County's Russell v. Boehringer Ingelheim Pharmaceuticals, Inc. (November 2024) produced a hung jury on bladder cancer causation. Multiple defense verdicts returned in California state courts.
Bellwether trials against Boehringer Ingelheim scheduled to begin March 14, 2028. Preserves innovator liability theory for brand-name manufacturers. GSK, Sanofi, and Pfizer resolved their Connecticut claims by late 2025; Boehringer Ingelheim remains the sole major defendant without a global settlement.
Federal MDL No. 9:20-md-02924 (S.D. Fla., Judge Robin L. Rosenberg) dismissed in 2022 after Daubert order excluding plaintiffs' general causation experts. Eleventh Circuit appeal pending following oral arguments in October 2025. August 2024 state court ruling in Wilson prostate cancer case excluded plaintiffs' general and specific causation experts, aligning with federal MDL.
Cook County's Valadez (May 2024) produced defense verdict for GSK and Boehringer Ingelheim against $640 million demand. Joiner (August 2024, Illinois) returned defense verdict for GSK on colorectal cancer claims.
Key defendants
GlaxoSmithKline LLC
Role: Brand Manufacturer
Delaware Supreme Court reversed Daubert ruling April 16, 2025, excluding plaintiffs' general causation experts. Major defense win on reliability standard; case No. 255, 2024.
Boehringer Ingelheim Pharmaceuticals, Inc.
Role: Brand Manufacturer
Named with corporate affiliates Boehringer Ingelheim Corporation and Ingelheim U.S.A. Corporation. Same Daubert reversal benefit; Delaware Supreme Court rejected 'liberal admissibility' standard.
Sanofi US Services Inc.
Role: Brand Manufacturer
Part of Sanofi defendant group with Sanofi-Aventis U.S. LLC and Chattem, Inc. Shielded by Delaware Supreme Court causation expert exclusion; no pending dispositive motions per July 1, 2024 order.
Pfizer Inc.
Role: Brand Manufacturer
Acquired OTC rights; named in MDL 2924 and Delaware. Delaware Supreme Court Daubert reversal creates significant causation hurdle for failure-to-warn and design defect claims.
Patheon Manufacturing Services, LLC
Role: Contract Manufacturer
CMO for Zantac in Delaware state court only. Delaware Supreme Court reversal applies equally; minimal unique exposure absent separate manufacturing defect theories.
| Defendant | Role | Intelligence Note |
|---|---|---|
| GlaxoSmithKline LLC | Brand Manufacturer | Delaware Supreme Court reversed Daubert ruling April 16, 2025, excluding plaintiffs' general causation experts. Major defense win on reliability standard; case No. 255, 2024. |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Brand Manufacturer | Named with corporate affiliates Boehringer Ingelheim Corporation and Ingelheim U.S.A. Corporation. Same Daubert reversal benefit; Delaware Supreme Court rejected 'liberal admissibility' standard. |
| Sanofi US Services Inc. | Brand Manufacturer | Part of Sanofi defendant group with Sanofi-Aventis U.S. LLC and Chattem, Inc. Shielded by Delaware Supreme Court causation expert exclusion; no pending dispositive motions per July 1, 2024 order. |
| Pfizer Inc. | Brand Manufacturer | Acquired OTC rights; named in MDL 2924 and Delaware. Delaware Supreme Court Daubert reversal creates significant causation hurdle for failure-to-warn and design defect claims. |
| Patheon Manufacturing Services, LLC | Contract Manufacturer | CMO for Zantac in Delaware state court only. Delaware Supreme Court reversal applies equally; minimal unique exposure absent separate manufacturing defect theories. |
Timeline
Valisure detects NDMA in ranitidine
Online pharmacy Valisure files citizen petition with FDA reporting NDMA contamination in ranitidine tablets exceeding 3,000,000 ng per tablet, far above the FDA's 96 ng acceptable daily intake limit. FDA confirms findings and issues safety warnings.
JPML creates MDL-2924
Judicial Panel on Multidistrict Litigation consolidates federal Zantac cases into MDL No. 2924 in the Southern District of Florida, assigned to Judge Robin L. Rosenberg. In re: Zantac (Ranitidine) Products Liability Litigation, No. 9:20-md-02924.
FDA orders market withdrawal
FDA requests all manufacturers withdraw every prescription and OTC ranitidine product from the U.S. market, citing evidence that NDMA levels increase under normal storage conditions.
Judge Rosenberg excludes all plaintiff experts
Judge Rosenberg issues 341-page Daubert order, 644 F. Supp. 3d 1075, excluding all ten plaintiffs' general causation experts as methodologically unreliable. Court finds experts cannot aggregate individually unreliable evidence to form reliable causation theory.
Final judgment entered in MDL
Rule 58 final judgment entered following summary judgment for all defendants, effectively terminating federal MDL after expert exclusion. Plaintiffs file notice of appeal to Eleventh Circuit on October 24, 2023.
Delaware trial judge admits plaintiff experts
Delaware Superior Court Judge Vivian Medinilla admits plaintiffs' general causation experts under 'liberal thrust' standard, framing causation around NDMA rather than ranitidine itself. In re Zantac (Ranitidine) Litig., No. 255, 2024.
GSK settles 80,000 state cases
GlaxoSmithKline agrees to pay up to $2.2 billion to resolve approximately 80,000 state-court claims, roughly 93% of its U.S. Zantac docket, without admission of liability. Settlement administered by BrownGreer LLC.
Delaware Supreme Court reverses expert ruling
Delaware Supreme Court unanimously reverses trial court in In re Zantac (Ranitidine) Litig., No. 255, 2024, 2025 WL 1903760 (Del. July 10, 2025), holding proper Daubert standard was not applied and remanding for stricter evaluation tying causation opinions to ranitidine itself.
Pfizer settles Connecticut claims
Pfizer reaches confidential settlements in Connecticut Zantac litigation. Sanofi separately settles approximately 4,000 cases. Both settlements follow GSK's earlier resolution.
Delaware judge dismisses 80,000 cases
Delaware Superior Court Judge Francis J. Jones grants summary judgment for all defendants, dismissing more than 80,000 pre-December 2025 filings after denying motion to supplement expert reports. Court holds plaintiffs 'not entitled to a mulligan' under Delaware causation law.
Statute of limitations
MDL 2924 (S.D. Fla., Judge Robin L. Rosenberg) was created February 6, 2020; Daubert ruling excluded plaintiffs' general causation experts December 2022, triggering remand of remaining cases. No MDL-wide tolling order currently in effect. FDA requested market withdrawal of all ranitidine products April 1, 2020 due to NDMA contamination risk. State SOL accrual dates vary by jurisdiction; April 2020 FDA action serves as reference date for discovery-rule analysis in most states.
Delaware
2 years
Rule: Del. Code Ann. tit. 10, § 8119 (personal injury); accrual standards pending resolution in In re: Zantac (Ranitidine) Litig., C.A. No. N22C-09-101 ZAN (Del. Super. Ct.)
Discovery: No ruling yet on whether discovery rule delays accrual until FDA's April 2020 withdrawal; court denied Patheon's motion to dismiss manufacturing/design defect claims June 16, 2025
Active state-court litigation before Judge Francis J. Jones, Jr.; no SOL-specific ruling in June 2025 order
| State | SOL | Rule | Discovery Rule | Notes |
|---|---|---|---|---|
| Delaware | 2 years | Del. Code Ann. tit. 10, § 8119 (personal injury); accrual standards pending resolution in In re: Zantac (Ranitidine) Litig., C.A. No. N22C-09-101 ZAN (Del. Super. Ct.) | No ruling yet on whether discovery rule delays accrual until FDA's April 2020 withdrawal; court denied Patheon's motion to dismiss manufacturing/design defect claims June 16, 2025 | Active state-court litigation before Judge Francis J. Jones, Jr.; no SOL-specific ruling in June 2025 order |
Live intelligence
AI litigation brief
Zantac remains active mdl with 194 current signals in the accepted feed.
Overview
The federal MDL 2924 remains procedurally dormant pending the Eleventh Circuit's decision on Judge Robin L. Rosenberg's Daubert dismissal, argued October 10, 2025; no ruling has issued as of September 2026. Delaware Superior Court Judge Francis J. Jones dismissed approximately 80,000 pre-December 2025 cases on April 13-14, 2026, applying the Delaware Supreme Court's July 10, 2025 mandate for stricter expert gatekeeping. Connecticut state court is now the sole active trial track, with bellwether trials against Boehringer Ingelheim scheduled to begin March 14, 2028.
Key developments
Trajectory
Court filings and press coverage are both active in MDL 2924, pointing to sustained litigation pressure rather than a one-off headline cycle. 6 live sources are contributing current context.
Editorial intelligence
MDL 2924 should stay on the lead docket watch because it is the primary consolidation vehicle for Zantac.
Generated Sep 30, 2026, 10:00 AM UTC
194 events detected
Google News (10)
Zantac Lawsuit Delaware Update (September 2026) - LawFold.com
Ranitidine Recall Lawsuit 2026: Eligibility and Payouts - LawFold.com
Zantac Lawsuit Settlement (Updated September 2026) - LawFold.com
Zantac Lawsuit: Settlements & Payouts (Aug 2026) - LawFold.com
Philly Judge Says Keller Postman Slowing Zantac Litigation - Law360
Judge Blasts Firm Trying to Kick Him Off Phila. Zantac Litigation - Law.com
Class Action Lawsuit Against Ranitidine: 2026 Guide - LawFold.com
Daubert for Dummies—Scientific Reliability in U.S. Courts: Daubert, Rule 702, and Made-for-Litigation Evidence - Genetic Literacy Project
Ranitidine Lawsuit 2026: Updates, Payouts, Eligibility - LawFold.com
How Long Will the Zantac Lawsuit Take? 2026 Guide - LawFold.com
Ecotoxicology and environmental safety • Shao B • PMID 42648038 • Journal Article.
DNA repair • Engelward BP • PMID 42566817 • Journal Article.
Environmental science & technology • Plata DL • PMID 42484880 • Journal Article.
Journal of the American Chemical Society • Swager TM • PMID 42425525 • Journal Article.
Zantac (Ranitidine) Products Liability Litigation
PACER docket filed in JPML: The plaintiffs are suing GlaxoSmithKline LLC, alleging that the medication Zantac (ranitidine) caused them to develop cancer. This lawsuit is part of a larger Multidistrict Litigation (MDL) where it is claimed that Zantac leads to cancer due to NDMA, a compound formed from the medication. The legal
Zantac (Ranitidine) Products Liability Litigation
PACER docket entry from PAED: COMPLAINT against All Defendants ( Filing fee $ 405 receipt number APAEDC-19687013.), filed by KELLIE BROWN. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(MASSLON, JOHN) (Entered: 09/28/2026)
Zantac (Ranitidine) Products Liability Litigation
PACER docket entry from PAED: COMPLAINT against All Defendants ( Filing fee $ 405 receipt number APAEDC-19686967.), filed by SHARRON DAILEY CUNNINGHAM-BEAMON. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(MASSLON, JOHN) (Entered: 09/28/2026)
Zantac (Ranitidine) Products Liability Litigation
PACER docket entry from PAED: COMPLAINT against all defts ( Filing fee $ 405 receipt number APAEDC-19686796.), filed by GREGORY HOPKINS. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(MASSLON, JOHN) Modified on 9/28/2026 (lvj). (Entered: 09/28/2026)
Zantac (Ranitidine) Products Liability Litigation
PACER docket entry from PAED: COMPLAINT against All Defendants ( Filing fee $ 405 receipt number APAEDC-19686688.), filed by CHARLENE SMITH. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(MASSLON, JOHN) (Entered: 09/28/2026)
Zantac (Ranitidine) Products Liability Litigation
PACER docket entry from PAED: COMPLAINT against All Defendants ( Filing fee $ 405 receipt number APAEDC-19658292.), filed by DEBORAH COOPER. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(MASSLON, JOHN) (Entered: 09/18/2026)
Zantac (Ranitidine) Products Liability Litigation
PACER docket entry from PAED: COMPLAINT against All Defendants ( Filing fee $ 405 receipt number APAEDC-19658285.), filed by PEGGY LIPSCOMB. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(MASSLON, JOHN) (Entered: 09/18/2026)
Zantac (Ranitidine) Products Liability Litigation
PACER docket entry from PAED: COMPLAINT against All Defendants ( Filing fee $ 405 receipt number APAEDC-19658269.), filed by AMY BIERNACKI. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(MASSLON, JOHN) (Entered: 09/18/2026)
Zantac (Ranitidine) Products Liability Litigation
PACER docket entry from PAED: COMPLAINT against All Defendants ( Filing fee $ 405 receipt number APAEDC-19658257.), filed by ALFREDERICK BLYDEN. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(MASSLON, JOHN) (Entered: 09/18/2026)
Zantac (Ranitidine) Products Liability Litigation
PACER docket entry from PAED: COMPLAINT against All Defendants ( Filing fee $ 405 receipt number APAEDC-19658249.), filed by SHIRLEY JACKSON. (Attachments: # 1 Civil Cover Sheet, # 2 Designation Form)(MASSLON, JOHN) (Entered: 09/18/2026)
Workbench
Sign in to save litigations, capture notes, and monitor live signals. Sign in for unlimited.
LexGenius Ranking
88Score
Court, news, and regulatory activity are elevated
Monitoring
Live
monitoring
Last: Sep 30, 2026, 10:00 AM UTC
Next: —
Source Monitoring
PACER
PACER
Google News
FAERS
PubMed
Event feed
194
events detected
AI Brief
Zantac remains active mdl with 194 current signals in the accepted feed.
Overview
The federal MDL 2924 remains procedurally dormant pending the Eleventh Circuit's decision on Judge Robin L. Rosenberg's Daubert dismissal, argued October 10, 2025; no ruling has issued as of September 2026. Delaware Superior Court Judge Francis J. Jones dismissed approximately 80,000 pre-December 2025 cases on April 13-14, 2026, applying the Delaware Supreme Court's July 10, 2025 mandate for stricter expert gatekeeping. Connecticut state court is now the sole active trial track, with bellwether trials against Boehringer Ingelheim scheduled to begin March 14, 2028.
Key developments
PACER court filing on Dec 31: Zantac (Ranitidine) Products Liability Litigation. ‖ LawFold.com news on Sep 13: Zantac Lawsuit Delaware Update (September 2026) - LawFold.com. ‖ openFDA recall on Jun 24: FDA Recall: Cetirizine Hydrochloride Tablets USP 5 mg, 100-count bottle,. ‖ PubMed research on Aug 26: Determination of 10 nitrosamines in stinky mandarin fish and cumulative health risk assessment across four dietary patterns..
Generated Sep 30, 2026, 10:00 AM UTC
Tracked MDLs
MDL 2924
S.D. Fla.
Zantac (ranitidine) products liability
← Previous
California Women's Prisons
Monitors litigation, oversight, and policy reporting involving abuse claims in California women’s prisons.
Next →
Abbott Spinal Cord Stimulators
Tracks pending JPML consolidation proceedings alleging Abbott spinal cord stimulator devices caused neurological injury, device migration, failed pain relief, and other serious complications.